← Leaderboards
David L Thomas
Johns Hopkins University
$44,227,388
Attributed
$52,051,502
Total exposure
17
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$51,763,031 · 16
AHRQ$288,471 · 1
By mechanism
R01$41,096,835 · 6
R37$6,966,384 · 1
U19$1,917,936 · 2
U54$1,662,970 · 2
R18$288,471 · 1
P51$118,906 · 2
Top collaborators
- Priya Duggal7 shared
- Ashwin Balagopal5 shared
- Risha Irvin5 shared
- Shruti H Mehta5 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Chloe L Thio$13,807,555
- Kathleen Schwarz$11,772,700
- Paula M Pitha-Rowe$8,862,652
- Gregory D Kirk$60,349,977
- Priya Duggal$4,703,374
Others in their field
Top investigators on “Hepatitis C Virus”
- Constance Ann Benson · University Of California, San Diego$150,079,712
- Sharon A Nachman · Johns Hopkins University$91,575,784
- Peter B. Gilbert · Fred Hutchinson Cancer Center$77,122,577
- Robert Turner Schooley · University Of Colorado Denver$45,719,253
- Charles R Rinaldo · University Of Pittsburgh At Pittsburgh$44,694,148
- Charles M. Rice · Rockefeller University$42,549,577
Research focus
Hepatitis C VirusHepatitis CHiv InfectionsPersonsInfectionLiverLiver DiseasesBaseAffectClinical ResearchGenesViral RnaPlasmaFibrosisHuman SubjectInjecting Drug UserSuccessVirus ReplicationTissuesChronicInsightCohortViralGrant
Grant awards (106)
Human Genetic determinants of HBV recovery$769,106
R01 · FY2025 · AI · contact PI
Clinical Project$521,980
U19 · FY2025 · AI · contact PI
Human Genetic determinants of HBV recovery$780,411
R01 · FY2024 · AI · contact PI
The Impact of HCV Treatment in HIV/HCV coinfected and HCV monoinfected Incarcerated Persons on HCV Elimination$736,715
R01 · FY2024 · DA
Interaction of Schistosomiasis mansoni and hepatitis B virus infections on hepatocellular carcinoma$317,396
U54 · FY2024 · CA · contact PI
The Impact of HCV Treatment in HIV/HCV coinfected and HCV monoinfected Incarcerated Persons on HCV Elimination$759,561
R01 · FY2023 · DA
Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugs$687,581
R01 · FY2023 · DA · contact PI
Interaction of Schistosomiasis mansoni and hepatitis B virus infections on hepatocellular carcinoma$351,257
U54 · FY2023 · CA · contact PI
Human Genetic determinants of HBV recovery$796,842
R01 · FY2022 · AI · contact PI
The Impact of HCV Treatment in HIV/HCV coinfected and HCV monoinfected Incarcerated Persons on HCV Elimination$769,782
R01 · FY2022 · DA
Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugs$687,760
R01 · FY2022 · DA · contact PI
Interaction of Schistosomiasis mansoni and hepatitis B virus infections on hepatocellular carcinoma$360,765
U54 · FY2022 · CA · contact PI
Human Genetic determinants of HBV recovery$800,431
R01 · FY2021 · AI · contact PI
The Impact of HCV Treatment in HIV/HCV coinfected and HCV monoinfected Incarcerated Persons on HCV Elimination$779,830
R01 · FY2021 · DA · contact PI
Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugs$664,100
R01 · FY2021 · DA · contact PI
Interaction of Schistosomiasis mansoni and hepatitis B virus infections on hepatocellular carcinoma$350,867
U54 · FY2021 · CA · contact PI
COVIDgene: Host genetics of SARS_CoV_2 infections$265,558
R01 · FY2021 · AI · contact PI
The Impact of HCV Treatment in HIV/HCV coinfected and HCV monoinfected Incarcerated Persons on HCV Elimination$826,337
R01 · FY2020 · DA · contact PI
Human Genetic determinants of HBV recovery$788,585
R01 · FY2020 · AI · contact PI
Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugs$708,571
R01 · FY2020 · DA · contact PI
COVIDgene: Host genetics of SARS_CoV_2 infections$531,120
R01 · FY2020 · AI · contact PI
Interaction of Schistosomiasis mansoni and hepatitis B virus infections on hepatocellular carcinoma$282,685
U54 · FY2020 · CA · contact PI
HIV HCV Coinfection Antiviral Therapy and Fibrosis$733,577
R37 · FY2019 · DA · contact PI
Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugs$727,804
R01 · FY2019 · DA · contact PI
HIV HCV Coinfection Antiviral Therapy and Fibrosis$733,577
R37 · FY2018 · DA · contact PI
HIV and Hepatitis C Pathogenesis & The Human Genome$720,712
R01 · FY2018 · DA · contact PI
Defining the effects of biological sex on patterns inflammatory gene expression in HIV an HIV/HVC coinfection$105,835
R37 · FY2018 · DA · contact PI
HIV HCV Coinfection Antiviral Therapy and Fibrosis$733,577
R37 · FY2017 · DA · contact PI
HIV and Hepatitis C Pathogenesis & The Human Genome$720,712
R01 · FY2017 · DA · contact PI
HIV and Hepatitis C Pathogenesis & The Human Genome$739,406
R01 · FY2016 · DA · contact PI
HIV HCV Coinfection Antiviral Therapy and Fibrosis$726,240
R37 · FY2016 · DA · contact PI
The Progression of Hepatitis C Among IDUs with HIV$687,429
R01 · FY2016 · DA
HIV and Hepatitis C Pathogenesis & The Human Genome$743,251
R01 · FY2015 · DA · contact PI
HIV HCV Coinfection Antiviral Therapy and Fibrosis$733,577
R37 · FY2015 · DA · contact PI
The Progression of Hepatitis C Among IDUs with HIV$703,923
R01 · FY2015 · DA
HIV and Hepatitis C Pathogenesis & The Human Genome$145,199
R01 · FY2015 · DA · contact PI
Dissemination of Patient-Centered Outcomes Research in Hepatitis C Virus to Infec$92,123
R18 · FY2015 · HS · contact PI
HIV and Hepatitis C Pathogenesis & The Human Genome$768,803
R01 · FY2014 · DA · contact PI
The Progression of Hepatitis C Among IDUs with HIV$719,084
R01 · FY2014 · DA · contact PI
HIV HCV Coinfection Antiviral Therapy and Fibrosis$621,175
R37 · FY2014 · DA · contact PI
Dissemination of Patient-Centered Outcomes Research in Hepatitis C Virus to Infec$96,348
R18 · FY2014 · HS · contact PI
The Progression of Hepatitis C Among IDUs with HIV$708,416
R01 · FY2013 · DA · contact PI
Hepatitis C Pathogenesis and the Human Genome$639,491
R01 · FY2013 · DA · contact PI
HIV HCV Coinfection Antiviral Therapy and Fibrosis$614,666
R37 · FY2013 · DA · contact PI
Dissemination of Patient-Centered Outcomes Research in Hepatitis C Virus to Infec$100,000
R18 · FY2013 · HS · contact PI
The Progression of Hepatitis C Among IDUs with HIV$749,282
R01 · FY2012 · DA · contact PI
Hepatitis C Pathogenesis and the Human Genome$694,428
R01 · FY2012 · DA · contact PI
HIV HCV Coinfection Antiviral Therapy and Fibrosis$646,848
R37 · FY2012 · DA · contact PI
The Progression of Hepatitis C Among IDUs$723,353
R01 · FY2011 · DA · contact PI
Hepatitis C Pathogenesis and the Human Genome$703,933
R01 · FY2011 · DA · contact PI
HIV HCV Coinfection Antiviral Therapy and Fibrosis$655,781
R37 · FY2011 · DA · contact PI
The Progression of Hepatitis C Among IDUs$743,105
R01 · FY2010 · DA · contact PI
Hepatitis C Pathogenesis and the Human Genome$723,283
R01 · FY2010 · DA · contact PI
HIV HCV Coinfection Antiviral Therapy and Fibrosis$661,531
R37 · FY2010 · DA · contact PI
The Progression of Hepatitis C Among IDUs$731,929
R01 · FY2009 · DA · contact PI
Hepatitis C Pathogenesis and the Human Genome$725,100
R01 · FY2009 · DA · contact PI
HIV HCV Coinfection Antiviral Therapy and Fibrosis$504,056
R01 · FY2009 · DA · contact PI
Clinical Core$298,538
U19 · FY2009 · AI · contact PI
The Progression of Hepatitis C Among IDUs$712,636
R01 · FY2008 · DA · contact PI
Hepatitis C Pathogenesis & The Human Genome$643,505
R01 · FY2008 · DA · contact PI
HIV HCV Coinfection Antiviral Therapy and Fibrosis$499,538
R01 · FY2008 · DA · contact PI
Clinical Core$291,383
U19 · FY2008 · AI · contact PI
HIV HCV Coinfection Antiviral Therapy and Fibrosis$100,529
R01 · FY2008 · DA · contact PI
The Progression of Hepatitis C Among IDUs$708,063
R01 · FY2007 · DA · contact PI
Hepatitis C Pathogenesis & The Human Genome$642,486
R01 · FY2007 · DA · contact PI
HIV HCV Coinfection Antiviral Therapy and Fibrosis$476,012
R01 · FY2007 · DA · contact PI
Clinical Core$268,476
U19 · FY2007 · AI · contact PI
The Progression of Hepatitis C Among IDUs$685,883
R01 · FY2006 · DA · contact PI
Hepatitis C Pathogenesis & The Human Genome$649,570
R01 · FY2006 · DA · contact PI
HIV HCV Coinfection Antiviral Therapy and Fibrosis$480,113
R01 · FY2006 · DA · contact PI
Clinical Core$273,327
U19 · FY2006 · AI · contact PI
GB VIRUS C INFECTION OF MACAQUES: AN HIV VACCINE MODEL$57,292
P51 · FY2006 · RR · contact PI
The Progression of Hepatitis C Among IDUs$754,753
R01 · FY2005 · DA
Hepatitis C Pathogenesis &The Human Genome$684,869
R01 · FY2005 · DA
HIV HCV Coinfection Antiviral Therapy and Fibrosis$485,135
R01 · FY2005 · DA
Clinical Core$264,232
U19 · FY2005 · AI
The Progression of Hepatitis C Among IDUs$65,000
R01 · FY2005 · DA
GB VIRUS C INFECTION OF MACAQUES: AN HIV VACCINE MODEL$47,962
P51 · FY2005 · RR
The Progression of Hepatitis C Among IDUs$753,773
R01 · FY2004 · DA
Hepatitis C Pathogenesis &The Human Genome$639,615
R01 · FY2004 · DA
HIV HCV COINFECTION--ANTIVIRAL THERAPY AND FIBROSIS$463,566
R01 · FY2004 · DA
GB VIRUS C INFECTION OF MACAQUES: AN HIV VACCINE MODEL$13,652
P51 · FY2004 · RR
The Progression of Hepatitis C Among IDUs$696,769
R01 · FY2003 · DA
HIV HCV COINFECTION--ANTIVIRAL THERAPY AND FIBROSIS$458,130
R01 · FY2003 · DA
HEPATITIS C PATHOGENESIS &THE HUMAN GENOME$329,892
R01 · FY2003 · DA
HEPATITIS C PATHOGENESIS &THE HUMAN GENOME$142,666
R01 · FY2003 · DA
The Progression of Hepatitis C Among IDUs$713,629
R01 · FY2002 · DA
HIV HCV COINFECTION--ANTIVIRAL THERAPY AND FIBROSIS$408,641
R01 · FY2002 · DA
HIV, DRUG USE AND HEPATITIS C PATHOGENESIS$406,266
R01 · FY2002 · DA
HEPATITIS C PATHOGENESIS &THE HUMAN GENOME$320,581
R01 · FY2002 · DA
INTERFERON ALPHA 2B &ORAL RIBAVIRIN COMBINATION THERAPY FOR HEPATITIS C IN HIV$0
M01 · FY2002 · RR
INTRON A + RIBAVIRIN IN PATIENTS WITH HEPATITIS C NOT TREATED WITH INTERFERON$0
M01 · FY2002 · RR
HEPATITIS C IN DRUG USERS--EFFECTS OF HIV AND OTHER FACTORS$0
M01 · FY2002 · RR
HIV, DRUG USE AND HEPATITIS C PATHOGENESIS$487,645
R01 · FY2001 · DA
HIV HCV COINFECTION--ANTIVIRAL THERAPY AND FIBROSIS$468,440
R01 · FY2001 · DA
HEPATITIS C PATHOGENESIS &THE HUMAN GENOME$319,273
R01 · FY2001 · DA
HEPATITIS C IN DRUG USERS--EFFECTS OF HIV AND OTHER FACTORS$0
M01 · FY2001 · RR
INTRON A + RIBAVIRIN IN PATIENTS WITH HEPATITIS C NOT TREATED WITH INTERFERON$0
M01 · FY2001 · RR
INTERFERON ALPHA 2B &ORAL RIBAVIRIN COMBINATION THERAPY FOR HEPATITIS C IN HIV$0
M01 · FY2001 · RR
HIV HCV COINFECTION--ANTIVIRAL THERAPY AND FIBROSIS$464,526
R01 · FY2000 · DA
HIV, DRUG USE AND HEPATITIS C PATHOGENESIS$363,263
R01 · FY2000 · DA
HEPATITIS C PATHOGENESIS &THE HUMAN GENOME$338,079
R01 · FY2000 · DA
HIV, DRUG USE AND HEPATITIS C PATHOGENESIS$59,000
R01 · FY2000 · DA
INTERFERON ALPHA 2B &ORAL RIBAVIRIN COMBINATION THERAPY FOR HEPATITIS C IN HIV$0
M01 · FY2000 · RR
INTRON A + RIBAVIRIN IN PATIENTS WITH HEPATITIS C NOT TREATED WITH INTERFERON$0
M01 · FY2000 · RR
HEPATITIS C IN DRUG USERS--EFFECTS OF HIV AND OTHER FACTORS$0
M01 · FY2000 · RR